Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Icl Group Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Icl Group Ltd trades at $4.87 (market cap $6.30B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.3× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.93% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ICL | |
|---|---|---|
Market Cap | $39.89B | $6.30B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $7.07 |
52-Week Low | $278.09 | $4.80 |
Enterprise Value | $38.15B | $8.87B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ICL trades at $4.85, unchanged on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 earnings of $0.11 per share, beating expectations, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion, with a net income margin of 3.52% and a P/E ratio of 23.1. Analyst consensus is entirely Hold, with no Buy or Sell ratings among the four covering firms.
ICL faces headwinds from declining profit margins and elevated raw material costs, but operational improvements and raised 2026 EBITDA guidance offer some upside. Key risks include geopolitical tensions and foreign exchange volatility. The stock's current valuation appears fair, with limited near-term catalysts given the neutral analyst sentiment and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
